Related Experiment Video
Updated: Jul 16, 2026
09:33
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Inhibiting kinases in malignant gliomas
1Center For Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Shields-Warren 430D, 44 Binney Street, Boston, MA 02115, USA.
Expert Opinion on Therapeutic Targets
|March 22, 2007
Summary
Targeted molecular agents, particularly kinase inhibitors, show promise for treating malignant gliomas by regulating key cell signaling pathways. Future strategies aim to enhance the modest activity observed in early clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Malignant gliomas are aggressive brain tumors with complex pathogenesis.
- Protein kinases are crucial regulators of cellular processes implicated in glioma growth and spread.
- Targeted molecular therapies, including kinase inhibitors, are emerging as potential treatment strategies.
Purpose of the Study:
- To review key protein kinases involved in malignant gliomas.
- To summarize the current clinical development of kinase inhibitors for glioma treatment.
- To discuss strategies for improving the efficacy of these targeted agents.
Main Methods:
- Literature review of protein kinases in glioma.
- Analysis of existing clinical trial data for kinase inhibitors.
- Discussion of therapeutic strategies and future directions.
Main Results:
- Kinase inhibitors are generally well-tolerated in clinical settings.
- Current kinase inhibitors exhibit modest therapeutic activity against malignant gliomas.
- Early trials provide valuable insights for optimizing future drug development.
Conclusions:
- Understanding glioma pathogenesis fuels the development of targeted kinase inhibitors.
- Further research and strategic improvements are needed to enhance the effectiveness of kinase inhibitors in treating malignant gliomas.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...